New Approaches to Using FEIBA in the Treatment of Inhibitor Patients

ABSTRACT

Managing hemophilia becomes particularly difficult in patients with inhibitory antibodies, especially in those requiring surgery or with refractory bleeding events. Equally challenging are those patients who develop autoantibodies against factor VIII (FVIII) in the absence of a prior history of FVIII deficiency (acquired hemophilia). Physicians seeking both short- and long-term treatment strategies for bleeding events must often rely on FVIII-bypassing agents such as activated prothrombin complex concentrate (e.g., factor eight bypassing activity [FEIBA VH, Baxter BioScience, Westlake Village, CA]) or recombinant factor VIIa (rFVIIa [NovoSeven, NovoNordisk, Bagsvaerd, Denmark]). Surgical procedures in patients with inhibitors present a considerable challenge, from both a risk-benefit and a cost-benefit aspect. Hemostasis is difficult to achieve in these patients and new treatment options are being explored. Similarly challenging are refractory bleeds, the management of which is likely to benefit from a systematic treatment approach.

KEYWORDS

Autoantibodies - acquired hemophilia - FVIII-bypassing agents - refractory bleeds - surgery

REFERENCES

• 1 Knight R, Stanley S, Wong M, Dolan G. Hemophilia therapy and blood-borne pathogen risk.  Semin Thromb Hemost. 2006;  32(suppl 2) 3-9
• 2 Ludlam C. Identifying and managing inhibitor patients requiring orthopaedic surgery-the multidisciplinary team approach.  Haemophilia. 2005;  11(suppl 1) 7-10
• 3 Berntorp E, Boulyjenkov V, Brettler D et al.. Modern treatment of haemophilia.  Bull World Health Organ. 1995;  73 691-701
• 4 Hilgartner M W, Makipernaa A, Dimichele D M. Long-term FEIBA prophylaxis does not prevent progression of existing joint disease.  Haemophilia. 2003;  9 261-268
• 5 Paisley S, Wight J, Currie E, Knight C. The management of inhibitors in haemophilia A: introduction and systematic review of current practice.  Haemophilia. 2003;  9 405-417
• 6 Lloyd Jones M, Wight J, Paisley S, Knight C. Control of bleeding in patients with haemophilia A with inhibitors: a systematic review.  Haemophilia. 2003;  9 464-520
• 7 Green D, Rademaker A W, Briet E. A prospective, randomized trial of prednisone and cyclophosphamide in the treatment of patients with factor VIII autoantibodies.  Thromb Haemost. 1993;  70 753-757
• 8 Leissinger C A. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.  Am J Hematol. 2004;  77 187-193
• 9 Kulkarni R, Soucie J M, Evatt B. Renal disease among males with haemophilia.  Haemophilia. 2003;  9 703-710
• 10 Darby S C, Keeling D M, Spooner R J et al.. The incidence of factor VIII and factor IX inhibitors in the hemophilia population of the UK and their effect on subsequent mortality, 1977-99.  J Thromb Haemost. 2004;  2 1047-1054
• 11 Astermark J. Treatment of the bleeding inhibitor patient.  Semin Thromb Hemost. 2003;  29 77-85
• 12 Key N S. Inhibitors in congenital coagulation disorders.  Br J Haematol. 2004;  127 379-391
• 13 Berntorp E, Danfield S, Waters J et al.. The FEIBA vs. NovoSeven^® Comparative Study (FENOC)-a randomized evaluation of by-passing agents in hemophilia complicated by inhibitors.  Blood. 2005;  106 abst 324
• 14 Di Michele D M. Immune tolerance: a synopsis of the international experience.  Haemophilia. 1998;  4 568-573
• 15 Brackmann H H, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors-twenty years' ‘Bonn protocol’.  Vox Sang. 1996;  70(suppl 1) 30-35
• 16 Oldenburg J, Schwaab R, Brackmann H H. Induction of immune tolerance in haemophilia A inhibitor patients by the 'Bonn Protocol': predictive parameter for therapy duration and outcome.  Vox Sang. 1999;  77(suppl 1) 49-54
• 17 Valentino L A, Salit M G. Prophylactic use of FEIBA in children with hemophilia complicated by high-titered inhibitors.  Blood. 2002;  100(suppl) 102B (abst 3886)
• 18 Gringeri A A. Prospective, randomized, cross-over study of an activated prothrombin complex concentrate for secondary prophylaxis in patients with hemophilia a and inhibitors (PRO-FEIBA). Paper presented at: XVth Annual Hemophilia Research Study Update Meeting January 21-24, 2005 San Juan, Puerto Rico;
• 19 Rodriguez-Merchan E C, Wiedel J D, Wallny T et al.. Elective orthopaedic surgery for inhibitor patients.  Haemophilia. 2003;  9 625-631
• 20 Tjonnfjord G E, Brinch L, Gedde-Dahl T, Brosstad F R. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX.  Haemophilia. 2004;  10 174-178
• 21 Gringeri A, Mantovani L G, Scalone L, Mannucci P M. Cost of care and quality of life for patients with hemophilia complicated by inhibitors: the COCIS Study Group.  Blood. 2003;  102 2358-2363
• 22 Negrier C, Tjonnfjord G, Kraut E, Giangrande P, Ewenstein B. Efficacy of FEIBA in surgical and invasive procedures.  Haemophilia. 2004;  10(suppl 3) 53-66
• 23 Negrier C. Current and Future approaches to inhibitor management and aversion - part 2. Paper presented at: XVth Annual Hemophilia Research Study Update Meeting January 21-24, 2005 San Juan, Puerto Rico;
• 24 Barrowcliffe T W. Monitoring haemophilia severity and treatment: new or old laboratory tests?.  Haemophilia. 2004;  10(suppl 4) 109-114
• 25 Varadi K, Negrier C, Berntorp E et al.. Monitoring the bioavailability of FEIBA with a thrombin generation assay.  J Thromb Haemost. 2003;  1 2374-2380
• 26 Key N S, Christie B, Henderson N, Nelsestuen G L. Possible synergy between recombinant factor VIIa and prothrombin complex concentrate in hemophilia therapy.  Thromb Haemost. 2002;  88 60-65
• 27 Ng H J, Loh S M, Tan D C, Lee L H. Thrombosis associated with the use of recombinant activated factor VII: profiling two events.  Thromb Haemost. 2004;  92 1448-1449
• 28 Rosenfeld S B, Watkinson K K, Thompson B H, Macfarlane D E, Lentz S R. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient.  Thromb Haemost. 2002;  87 925-926
• 29 Schneiderman J, Nugent D J, Young G. Sequential therapy with activated prothrombin complex concentrate and recombinant factor VIIa in patients with severe haemophilia and inhibitors.  Haemophilia. 2004;  10 347-351
• 30 Key N. Current and Future Approaches to Inhibitor Management and Aversion - part 2. Paper presented at: XVth Annual Hemophilia Research Study Update Meeting January 21-24, 2005 San Juan, Puerto Rico;
• 31 Nogami K, Shima M, Giddings J C et al.. Circulating factor VIII immune complexes in patients with type 2 acquired hemophilia A and protection from activated protein C-mediated proteolysis.  Blood. 2001;  97 669-677 , Erratum in: Blood 2001; 97:1542
• 32 Baudo F, de Cataldo F. Acquired hemophilia: a critical bleeding syndrome.  Haematologica. 2004;  89 96-100
• 33 Collins P, Baglin T, Brown S et al.. UKHCDO Acquired Haemophilia Study: A Complete National Cohort. Paper presented at: 47th Annual Meeting and Exposition of the American Society of Hematology December 10-13, 2005 Atlanta, GA;
• 34 Green D, Lechner K. A survey of 215 non-hemophilic patients with inhibitors to factor VIII.  Thromb Haemost. 1981;  45 200-203
• 35 Hauser I, Lechner K. Solid tumors and factor VIII antibodies.  Thromb Haemost. 1999;  82 1005-1007
• 36 Bossi P, Cabane J, Ninet J et al.. Acquired hemophilia due to factor VIII inhibitors in 34 patients.  Am J Med. 1998;  105 400-408
• 37 Sallah S, Wan J Y. Inhibitors against factor VIII in patients with cancer. Analysis of 41 patients.  Cancer. 2001;  91 1067-1074
• 38 Nemes L, Pitlik E. New protocol for immune tolerance induction in acquired hemophilia.  Haematologica. 2000;  85 64-68
• 39 Roberts H R, Monroe III D M, Hoffman M. Safety profile of recombinant factor VIIa.  Semin Hematol. 2004;  41 101-108
• 40 Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application.  Haemophilia. 2004;  10(suppl 2) 10-16